If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Structure, Staffing and Budgets
Download FREE Excerpt
10 Info Graphics
20 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
With the pandemic waning, Medical Affairs leaders must decide what is the right hybrid model for each organization: continue to work remotely, return to all in-person, or develop a flexible hybrid approach?
This Best Practices, LLC study examines the changing forms, features, conditions, and triggers for hybrid work models that are best suited for a flexible and resilient Medical Affairs organization.
This primary care research project probes and profiles how different medical organizations are using technology, shifting and shaping staff roles, adjusting remote vs. in-person work schedules, shrinking or expanding facilities, and planning post-pandemic.
Medical Affairs leaders can use to this report to develop a hybrid work model that is best suited for their organization.
I. Types of Work Models
The study engaged 51 Medical leaders from 39 pharma companies.
Pharmaceutical; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Communications; Clinical Research; Laboratories
Alexion Pharmaceuticals; Asklepion Pharmaceuticals; LLC; ASC Therapeutics; AstraZeneca; Baxter BioScience; Bayer; Boehringer Ingelheim; Bionorica SE; Cipla; Eisai; Elevation Oncology; Lilly; Ferozsons Laboratories Limited; GE Healthcare; Grifols; Heron Therapeutics; Incyte; Ipsen; Jazz Pharmaceuticals; Kinnate Biopharma; MerckSerono; Merz Aesthetics; NexGen Healthcare; Novartis; Novavax; OPEN Health; Orchard Therapeutics; OTSUKA; Pfizer; Roche; Sage Therapeutics; Sandoz; Sanofi; Santen; Servier; Supernus; Terumo Corporation; Teva Pharmaceutical Industries Ltd; UCB Pharma
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.